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Abstract The interaction of the CD40 receptor with its ligand 
has been shown to be crucial for the activation of B-lymphocytes. 
Here, we provide evidence that the pg39 molecule/CD40 ligand 
(gp39/CD40L) also functions as a stimulatory molecule for T-
lymphocytes. Activation of T-lymphocytes via gp39/CD40L 
induced a strong activation of Jun-N-terminal kinase (JNK) 
and p38-K. Activation of these kinases correlates with a 
stimulation of Racl and inhibition of Racl prevents gp39/ 
CD40L triggered JNK/p38-K activation. Further, cellular 
stimulation via the CD40 ligand results in tyrosine phosphoryla-
tion of cellular proteins and the activation of p56 lck. Inhibition of 
src-like kinases inhibits Racl as well as JNK7p38-K stimulation 
suggesting a signalling cascade from the gp39/CD40L via p56 lck 
and Racl to JNK/p38-K. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The interaction of B- and T-lymphocytes is essential for 
proliferation, differentiation, isotype switching and survival 
of B-lymphocytes [1,2]. In particular, the binding of the 
CD40 receptor on B-cells to the CD40 ligand (CD40L, also 
named gp39 or TRAP) expressed on T-lymphocytes seems to 
be very important for B-lymphocyte activation, since muta-
tions of gp39/CD40L result in the X-linked hyper-IgM syn-
drome. This immunodeficiency syndrome is characterized by 
normal or elevated IgM levels and inefficient isotype switching 
due to impaired stimulation of B-lymphocytes [3-6]. Patients 
suffer from severe, recurrent bacterial infections and a higher 
incidence of autoimmune diseases and malignancies. 
However, some data indicate that binding of the gp39/ 
CD40L to the CD40 receptor may activate not only B- but 
also T-lymphocytes [7-10]. The best evidence for this hypoth-
esis is provided by CD40 receptor knock-out mice. These mice 
lack germinal centers and the formation of germinal centers 
during an immune response can be initiated by injection of 
soluble CD40-Fc molecules. This implies that cellular stimu-
lation of T-lymphocytes via the gp39/CD40L has a crucial 
function in the initiation of germinal center formation. 
The gp39/CD40L is a 30 k D a type II membrane glycopro-
tein expressed on T-lymphocytes, but also on mast cells, ba-
sophils, N K cells, monocytes and even on B-lymphocytes [11 -
15]. H u m a n or mouse gp39/CD40L consists of 261 or 260 
amino acids, respectively, with a 22 amino acid cytoplasmic 
amino-terminal tail lacking any known enzymatic activity [2]. 
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The cytoplasmic domains of mouse and human gp39/CD40L 
are highly homologous with 82% identical residues [2] imply-
ing an important role of the cytoplasmic domain for the func-
tion of gp39/CD40L. Furthermore, gp39/CD40L exhibits sig-
nificant homology to the tumor necrosis factor, Fas and 
CD30 ligands [2]. 
In the present study we tested the hypothesis that gp39/ 
CD40L functions as a stimulatory molecule for T-lympho-
cytes and we aimed to identify signalling events initiated by 
gp39/CD40L. The results show a gp39/CD40L triggered acti-
vation of JNK/p38 kinases, which seems to be mediated by 
the src-like tyrosine kinase p56 l ck and the small G-protein 
R a c l . 
2. Materials and methods 
2.1. Cells, immunoprecipitation and immunoblotting 
All reagents were purchased from Sigma, if not otherwise cited. 
Human leukemic Jurkat or murine gp39/CD40L positive or negative 
EL4 T-lymphocytes [16] were grown in RPMI 1640 medium, 10% 
fetal calf serum, 10 mM HEPES (pH 7.4), 2 mM L-glutamine, 100 
uM non-essential amino acids, 1 mM sodium pyruvate, 100 units/ml 
penicillin, 100 Jig/ml streptomycin (all from Life Technologies, Eggen-
stein, Germany) and 50 uM [S-mercaptoethanol. Murine splenic T-
lymphocytes were purified by Ficoll gradient centrifugation and three 
times sorting by 1 h incubation with immobilized anti-CD3 (2C11). 
Finally, cells were incubated for 8 h with 10 ug/ml phytohemaggluti-
nin. FACS analysis showed that more than 90% of the cells were T-
cell receptor (TCR)/CD3 and gp39/CD40L positive. For activation, 
cells were washed twice and stimulated at 37°C with 2 ug/ml mono-
clonal anti-human or anti-mouse gp39/CD40L antibody (Pharmingen, 
San Diego, CA, USA) or isotype matched hamster or mouse immu-
noglobulins (Dianova, Hamburg, Germany). In addition, EL4 cells 
were also activated by 1 ug/ml purified CD40 receptor. Stimulation 
was terminated by lysis in 25 mM HEPES (pH 7.4), 0.1% SDS, 0.5% 
sodium deoxycholate, 1% Triton X-100, 125 mM NaCl, 10 mM each 
sodium fluoride, Na;jV04 and sodium pyrophosphate and 10 ug/ml 
each of aprotinin and leupeptin (RIPA buffer). Post-centrifugation 
supernatants were added to 5 X SDS sample buffer and 5% P-mercap-
toethanol (total cell lysates) or subjected to immunoprecipitation 
overnight at 4°C using 3 ug of each antibody/sample. For control 
immunoprecipitates, anti-gp39/CD40L stimulated samples were incu-
bated with irrelevant control immunoglobulins as indicated. Immuno-
complexes were immobilized by addition of protein A/G coupled 
agarose (Santa Cruz Inc.), washed, resuspended in reducing SDS sam-
ple buffer, separated by SDS/PAGE and transferred to polyvinyldi-
fluoride membranes (BioRad). Blots were incubated overnight at 4°C 
with the appropriate antibody (0.5 ug/ml) and developed by incuba-
tion with horseradish peroxidase conjugated protein G (BioRad) and 
use of a chemoluminescence kit (Amersham). 
CD40 receptor was purified from mouse splenic B-lymphocytes by 
immunoprecipitation with a monoclonal anti-CD40 receptor antibody 
(Pharmingen) as above. Immunoprecipitates were immobilized by ad-
dition of protein A/G coupled agarose followed by six times washing 
in RIPA buffer and three times in HEPES buffered saline solution (H/ 
S). CD40 receptor protein was eluted in 100 mM glycine (pH 3.0), 
immediately neutralized and dialysed against H/S. The purity of the 
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CD40 receptor preparat ion was determined by biotinylation, separa-
tion on 10% SDS/PAGE and visualization with horseradish peroxi-
dase coupled streptavidin (Amersham). The blots showed a single 
bland (plus the heavy and light chains of the ant i -CD40 receptor 
ant ibody used for purification) indicating the purity of the CD40 
receptor preparat ion. The concentrat ion of CD40 was calculated using 
a BioRad protein assay. The immunoglobulin concentrat ion was de-
termined by comparison with the values obtained using an irrelevant, 
isotype matched immunoglobulin in the purification process. The im-
munoglobulin content in the preparat ion was also estimated on the 
blots by comparison of the signal after HRP-streptavidin visualization 
with the signal of different amounts of normal , isotype matched im-
munoglobulin loaded on the same gel. The values were subtracted to 
get the CD40 receptor concentration. Since we used B-lymphocytes 
for the purification, this procedure should result in the purification of 
membrane CD40, which was confirmed by the size of the protein in 
blots. Cells were stimulated with 0.5 ng/ml of the purified receptor. 
CD40 receptor purification from splenocytes was performed to obtain 
stimulation of T-lymphocytes with a molecule displaying all natural 
modifications. 
2.2. Kinase and Racl assays 
For determination of J N K , p38-K or src-like tyrosine kinase activ-
ity, 8 X 1 0 6 cells were stimulated as above, lysed in R I P A buffer and 
subjected to immunoprecipitat ion using agarose coupled ant i -p56 k k or 
-p59 t y n , - J N K or -p38-K antibodies as described [17,18]. Immunopre-
cipitates were washed three times in lysis buffer and twice in kinase 
buffer (25 m M H E P E S (pH 7.0), 150 m M NaCl , 10 m M MnCl 2 , 1 m M 
N a 3 V 0 4 , 5 m M D T T , 0.5% NP40) for src-like kinases or twice in H/S, 
1% NP-40, 2 m M N a 3 V 0 4 , once in 100 m M Tris (pH 7.5), 0.1 M LiCl 
and twice in kinase buffer 12.5 m M M O P S (pH 7.5), 7.5 m M MgCl 2 , 
12.5 m M p-glycerophosphate and 0.5 m M each of N a F , E G T A and 
Na3"V04 for J N K and p38-K. Kinase reaction was started by addition 
of 30 ul kinase buffer supplemented with 10 u M A T P , [32P]yATP 
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Fig. 1. Activation of T-lymphocytes via gp39/CD40L with anti-gp39/CD40L antibodies or purified CD40 receptor proteins (EL4/CD40) stimu-
lates J N K (A) and p38-K (B). The activation of bo th kinases is inhibited by preincubation of the cells with the src-like tyrosine kinase inhibitor 
Herbimycin A (HA). Cells were lysed after stimulation via gp39/CD40L, J N K and p38-K were immunoprecipi tated and subjected to kinase as-
says with [32P]yATP and GST-c-Jun or GST-ATF-2 , respectively. Samples were separated by SDS-PAGE, blotted and analyzed by autoradiog-
raphy. Aliquots of the immunoprecipitates were blotted with an t i - JNK or anti-p38-K to test for similar amounts of protein in all lanes (small 
blots below). 
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(10 uCi/sample; 3000 Ci/mmol; NEN/DuPont) and 1 ng/ml GST-c-
Jun (amino acids 1-79) (for JNK) or GST-ATF-2 (amino acids 1-96) 
(for p38-K). Src-like kinase activity was determined by autophospho-
rylation. After 15 min incubation reducing SDS sample buffer was 
added, samples were separated on SDS/PAGE, blotted and autora-
diography was performed. The substrates GST-c-Jun and GST-ATF-2 
were expressed as described [18], 
Racl activity was determined in untransfected or N17Racl or 
pCEV and CD20 co-transfected Jurkat or EL4 cells after 4 h labelling 
with 1 mCi/ml 32P ;. Cells were stimulated as indicated and lysed in 25 
mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.2% SDS, 0.5% sodium 
deoxycholate, 20 mM MgCl2, 450 mM NaCl and 100 ug each of 
aprotinin and leupeptin. Racl was immunoprecipitated using a poly-
clonal, affinity purified anti-Racl antibody (Santa Cruz Inc.) and 
protein A/G conjugated agarose as described [18]. Immunoprecipitates 
were washed seven times in lysis buffer, once in 25 mM Tris-HCl (pH 
7.5), 0.1% Triton X-100, 1 mM MgCl2 and 125 mM NaCl and bound 
nucleotides were eluted in 1 mM EDTA at 68°C for 20 min. Samples 
were normalized for radioactivity and nucleotides were separated on 
polyethyleneimine-cellulose plates (Machery&Nagel) with 0.75 M 
KH2PO4 (pH 3.5). The thin layer chromatography plates were ana-
lyzed by autoradiography. 
2.3. Transfection assays 
Jurkat or EL4 cells were co-transfected with transdominant inhib-
itory pCEV/N17/?ac7 or vector control pCEV (each 50 Ug/20X106 
cells) with an expression vector for CD20 (pRc/CMV-crf20) (10 u.g) 
as previously described [18,19]. Since the ratio of 5:1 pCEV/ 
N177?ac/:pRc/CMV-a£?0 drives expression of N17Racl in any 
CD20 positive cell, the selection of CD20 positive cells via magnetic 
beads permits effective sorting for N17Racl expressing cells. In vivo 
labelling experiments showed that approximately 10% of all cells were 
CD20 positive, non-specific binding of the cells to the magnetic beads 
did not exceed 0.5% of all cells. Purified cells were allowed to recover 
for 30 min at 37°C and were then used for determination of JNK, 
p38-K or Racl activity. 
3. Results 
In order to identify signalling molecules which might be 
regulated by gp39/CD40L in T-lymphocytes, gp39/CD40L 
positive mouse EL4, human Jurkat or activated murine T-
lymphocytes were stimulated with monoclonal anti-gp39/ 
CD40L antibodies or purified CD40 receptor. Flow cytometry 
analysis revealed similar levels of gp39/CD40L expression on 
EL4, Jurkat and activated murine T-lymphocytes. Cellular 
stimulation via gp39/CD40L resulted in a rapid and strong 
activation of Jun-N-terminal kinase (JNK) and p38-K in all 
cell types (Fig. 1A,B). 
The activation of JNK-p38-K is regulated via different 
mechanisms including src-like tyrosine kinases [20]. We there-
fore investigated whether Herbimycin A, a src-like tyrosine 
kinase inhibitor, influences the activation of JNK/p38-K 
(Fig. 1A,B). Preincubation with Herbimycin A resulted in 
an almost complete inhibition of gp39/CD40L induced JNK/ 
p38-K activation. To further investigate a possible role of 
tyrosine kinases by the gp30/CD40L, we analyzed the activa-
tion of the src-like tyrosine kinases p56lck and p59fyn by gp39/ 
CD40L. These two kinases have been shown to have a crucial 
function in several signal transduction pathways in T-lympho-
cytes [21]. Cellular stimulation via gp39/CD40L using mono-
clonal anti-gp39/CD40L antibodies or purified CD40 receptor 
molecules induced an approximately 8-fold activation of 
p56lck in EL4 and Jurkat cells as well as in ex vivo mouse 
splenocytes (Fig. 2), whereas p59fyn was not stimulated by 
cellular triggering via gp39/CD40L. Activation of p56lck cor-
related with a tyrosine phosphorylation of several cellular 
proteins determined by blotting of whole cell lysates with 
the monoclonal anti-phosphotyrosine antibody 4G10 (not 
shown). 
In addition to a regulation by src-like tyrosine kinases, it 
has been reported that the activation of JNK and p38K de-
pends, at least under certain conditions, on the activity of 
Racl [20]. We therefore tested whether CD40 triggering stim-
ulates Racl. To this end Racl was immunoprecipitated from 
32P-labelled cells, bound guanine nucleotides were eluted and 
Jurkat Splenocytes 
p56lck 
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Fig. 2. Stimulation of Jurkat, EL4 or splenocytes via the gp39/CD40L results in activation of the tyrosine kinase p56lck. Jurkat, murine EL4 
cells or PHA stimulated murine splenocytes were incubated with monoclonal anti-gp39/CD40L antibodies or purified CD40 receptor (EL4/ 
CD40), lysed and subjected to immunoprecipitation with an anti-p56lck. The activity of immunoprecipitated p56lck was measured by autophos-
phorylation of the kinase followed by Western blotting and autoradiography. Non-specific immunoprecipitates (up) were performed with an ir-
relevant rabbit polyclonal antibody. An aliquot of the immunoprecipitates was blotted with anti-p56lck to test for similar amounts of p56lck in 
all lanes (small blots below). Shown are representative blots of three independent experiments. 
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Fig. 3. Gp39/CD40L triggering activates the small G-protein Racl which is prevented by preincubation with Herbimycin A (HA) (A). Inhibi-
tion of Racl by transfection of transdominant inhibitory N17Racl blocks activation of JNK and p38-K upon gp39/CD40L mediated cell acti-
vation (B). The efficiency of N17Racl expression is indicated by an almost complete inhibition of endogenous Racl activation after gp39/ 
CD40L triggering (C). For determination of Racl activity cells were transfected with N17Racl or vector control, or left untransfected, metabol-
ically labelled with 32P;, stimulated via gp39/CD40L and Racl was immunoprecipitated. Guanine nucleotides bound to immunoprecipitated 
Racl were eluted, separated by thin layer chromatography and analyzed by autoradiography. Experiments were repeated three times. JNK and 
p38-K activity was determined as above. 
separated by TLC. The results show that gp39/CD40L trigger-
ing results in a rapid stimulation of Racl, which was inhibited 
by Herbimycin A pretreatment (Fig. 3A). This suggests that 
src-like tyrosine kinases are involved in Racl stimulation by 
gp39/CD40L. To further test the function of Racl for JNK/ 
p38-K activation, we transiently transfected a transdominant 
inhibitory N17Racl construct blocking the activation of en-
dogenous Racl. These inhibitory constructs bind guanine nu-
cleotide exchange factors for small G-proteins with a very 
high affinity and specificity. This prevents the exchange of 
guanine nucleotides on a small G-protein without affecting 
the binding of GDP to e.g. endogenous Racl [22]. Expression 
of this construct almost completely prevented the activation of 
JNK and p38-K by gp39/CD40L (Fig. 3B). The efficiency of 
N17Racl transfection was determined by measuring Racl ac-
tivity after gp39/CD40L triggering. The results show an inhib-
ition of Racl stimulation in cells expressing N17Racl, where-
as transfection of the control vector did not alter anti-gp39/ 
CD40L induced Racl activation (Fig. 3C). 
The results presented above point to a novel pathway 
elicited by gp39/CD40L in T-lymphocytes. To further prove 
the specificity of the observed signalling events, gp39/CD40L 
negative or positive EL4 and Jurkat cells were stimulated with 
anti-gp39/CD40L antibodies or isotype matched irrelevant im-
munoglobulins. Treatment of gp39/CD40L negative EL4 cells 
did not result in any of the activation events observed after 
stimulation of gp39/CD40L positive EL4 or Jurkat cells (Fig. 
4A,B). Likewise, incubation of gp39/CD40L positive T-cells 
with isotype matched irrelevant immunoglobulins did not trig-
ger the stimulation of JNK, p38-K, p56lck (Fig. 4A) or Racl 
(Fig. 4B). These results indicate a specific activation of the 
observed signalling cascade by the gp39/CD40L. 
4. Discussion 
The present study provides evidence for a novel role of the 
gp39/CD40L: in addition to its function as a ligand for the 
CD40 receptor on B-lymphocytes it also seems to function as 
a signalling molecule on T-lymphocytes mediating T-cell acti-
vation. The blockade of JNK/p38-K stimulation by Herbimy-
cin A pretreatment and inhibition of Racl/2 points to a se-
quential activation of JNK and p38-K via Rac proteins and 
Herbimycin A sensitive kinases, e.g. p56lck. 
Activation of JNK/p38-K after gp39/CD40L triggering was 
observed in mouse and human T-lymphocytes as well as in ex 
vivo splenic T-lymphocytes. Since two different monoclonal 
antibodies specific for human or mouse gp39/CD40L, respec-
tively, were applied in the present study, it seems unlikely that 
the observed activation signals are mediated by a non-specific 
cross-reaction with another surface molecule. In addition, iso-
type matched immunoglobulins did not activate gp39/CD40L 
positive EL4 or Jurkat T-lymphocytes. Finally, gp39/CD40L 
negative EL4 cells did not respond to stimulation with anti-
gp39/CD40L antibodies. However, to further exclude the pos-
sibility of cellular stimulation via cross-reaction of the anti-
body with another surface molecule we purified CD40 recep-
tor from mouse splenic B-lymphocytes and used the purified 
CD40 receptor molecules for stimulation of EL4 cells. Purified 
CD40 receptor induced the same signalling events as observed 
upon stimulation with the antibodies indicating the specificity 
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Fig. 4. Activation of human Jurkat or murine gp39/CD40L positive (gp39/CD40L+) EL4 T-lymphocytes via p39/CD40L specifically activates 
JNK, p38-K, p56lck (A) and Racl (B), whereas gp39/CD40L negative (gp39/CD40L~) EL4 cells did not respond to stimulation with anti-gp39/ 
CD40L or purified CD40. Likewise, incubation of gp39/CD40L positive EL4 or Jurkat cells with isotype matched immunoglobulins does not 
result in cellular stimulation. Western blotting of aliquots of the indicated kinases shows that similar amounts of protein were loaded in all 
lanes (small blots). These results show the specificity of the observed signalling cascade upon activation of T-lymphocytes via gp39/CD40L. 
of the observed activation events for the gp39/CD40L. The 
anti-CD40 receptor antibody used for purification, which is 
also present in the CD40 preparat ion does not bind to EL4 or 
Jurkat cells as determined by FACS analysis. 
The stimulation of J N K and p38-K upon gp39/CD40L trig-
gering might be involved in the regulation of gene expression, 
in particular in the formation of a functional AP-1 complex. 
Activation of AP-1 after gp39/CD40L triggering may result in 
IL-2 synthesis, a crucial event for T-cell stimulation [23]. The 
stimulation of p38-K may trigger phosphorylation of ATF-1 
and ATF-2, which might also be involved in the formation of 
functional AP-1 or might interact with N F - K B [24,25]. Thus, 
p38-K may synergistically interact with J N K in the regulation 
of transcription. Further, the stimulation of p38-K could have 
additional functions, in particular phosphorylation of heat 
shock protein HSP 25/27 [26]. However, the exact role of these 
kinases for gp39/CD40L signalling has yet to be elucidated. 
Several receptors including the B-cell receptor (BCR), TCR/ 
C D 3 , CD40 or Fas have been shown to activate src-like ty-
rosine kinases, whereas only some of these receptors, e.g. the 
CD40 or Fas receptor, stimulate JNK/p38-K without co-stim-
ulation [27-30]. Thus, p56lck might be necessary but not suffi-
cient for JNK/p38-K stimulation and additional gp39/CD40L 
but not T C R / C D 3 or BCR elicited signals may exist and act 
together with p56l c k. 
Several studies support our results that gp39/CD40L has a 
dual function resulting in activation of both T- and B-lym-
phocytes, upon binding to the CD40 receptor. 
First, the best evidence for a stimulatory function of the 
gp39/CD40L for T-lymphocytes is provided by CD40 receptor 
knock-out mice, which lack germinal centers [7]. Co-injection 
of the antigen D N P - K L H with CD40-Fc restores the forma-
tion of germinal centers suggesting that stimulation of T-lym-
phocytes via gp39/CD40L has a crucial function in the initia-
tion of germinal center formation. 
Second, stimulation of activated peripheral T-cells via gp39/ 
CD40L increased T C R / C D 3 induced IL-4 synthesis and pro-
liferation [8,9]. 
Third, a signalling function of the gp39/CD40L is also sup-
ported by the finding that other ligands of the tumor necrosis 
factor/nerve growth factor- eceptor family, in particular the 
CD30 ligand, exhibit similar dual functions [31,32]. 
However, application of activating CD40 receptor antibod-
ies to gp39/CD40L knock-out mice restores cellular and hu-
moral immune responses to adenoviral vectors via a B7.2-
CD28 dependent mechanism [33]. Thus, gp39/CD40L may 
not be absolutely required for the stimulation of T-cells under 
these conditions and gp39/CD40L may function predomi-
nantly as a co-stimulatory molecule which can be replaced 
by other strong co-stimuli or by upregulation of other stim-
ulatory receptors replacing the function of gp39/CD40L in 
these knock-out mice. It might also be possible that the func-
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tion of gp39/CD40L as a signalling molecule is restricted to T-
lymphocytes in the germinal center [7] or to a certain sub-
population of peripheral T-lymphocytes. 
Since interaction of gp39/CD40L with the CD40 receptor 
results in a downregulation and internalization of the gp39/ 
CD40L [10], the observed signalling events elicited by gp39/ 
CD40L may be involved in a negative regulation of the inter-
action between gp39/CD40L and the CD40 receptor. In par-
ticular, Rac l has been shown to play an important role in 
actin cytoskeleton regulation [34] and Rac l activation might 
be involved in the internalization of the gp39/CD40L. This 
may limit the activation of B-lymphocytes. Thus, the observed 
signalling events could be involved in a negative regulation of 
B-lymphocyte activation by T-lymphocytes via the CD40 
ligand/CD40 receptor system. 
The present study suggests that gp39/CD40L activates 
JNK7p38-K via the src-like tyrosine kinase p56 l ck and Rac 
proteins. Since gp39/CD40L is predominantly expressed on 
activated, CD4+ T-lymphocytes [9,35,36], the stimulation of 
these cells by gp39/CD40L may result in a selective activation 
and proliferation of antigen specific T-lymphocytes, at least in 
germinal centers, after interaction with CD40 receptor posi-
tive antigen presenting cells. 
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